Bronchitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bronchitis. 80 active patents protecting 4 drugs from 3+ originators. First major cliff: 2031. Daily refresh.

4
Approved drugs
80
Active US patents
70/100
Avg vulnerability
—
Annual revenue covered

Originators in Bronchitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 70 patents Bristol-Myers Squibb 8 patents Generic (originally Pfizer) 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bronchitis. Each bar = one year. Y-axis scaled to peak year (32 patents).

3
26
4
27
7
28
6
29
1
31
7
32
7
35
2
36
6
37
4
38
32
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Epipen
epinephrine
 Pfizer Inc. 70 61 — 2026-12-12
Acetadote
Acetylcysteine
 Bristol-Myers Squibb 8 64 — 2031-07-21
Suprax
CEFIXIME
 — 1 75 — 2028-12-14
Vibramycin
doxycycline
 Generic (originally Pfizer) 1 80 — 2027-12-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7749532 Vibramycin method of use 80 2027-12-19
9233112 Suprax method of use 75 2028-12-14
11173209 Epipen method of use 75 2038-02-06
11173209 Epipen method of use 75 2038-02-06
11744895 Epipen method of use 75 2039-02-06
11717571 Epipen method of use 75 2039-02-06
11918655 Epipen method of use 75 2039-02-06
10682414 Epipen method of use 75 2039-02-06
11191838 Epipen method of use 75 2039-02-06
11717571 Epipen method of use 75 2039-02-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10130592 Epipen formulation 42 2035-03-13
9119876 Epipen formulation 42 2035-03-13
9119876 Epipen formulation 42 2035-03-13
9427421 Acetadote formulation 48 2032-05-08
9427421 Acetadote formulation 48 2032-05-08
8021344 Epipen formulation 48 2029-11-02
10653646 Epipen formulation 50 2039-03-21
11207280 Epipen formulation 50 2039-03-21
11207280 Epipen formulation 50 2039-03-21
10653646 Epipen formulation 50 2039-03-21

Related